Journal
BMC CLINICAL PATHOLOGY
Volume 6, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/1472-6890-6-2
Keywords
-
Categories
Funding
- Manitoba Medical Services Foundation
- Health Sciences Research Foundation, Winnipeg. Roche Molecular Biochemicals, Mannheim, Germany
Ask authors/readers for more resources
Background: The clinical benefit of determining the status of HER-2/neu amplification in breast cancer patients is well accepted. Although immunohistochemistry (IHC) is the most frequently used method to assess the over-expression of HER-2 protein, fluorescent in-situ hybridization (FISH) is recognized as the gold standard for the determining of HER-2/neu status. The greatest discordance between the two methods occurs among breast tumors that receive an indeterminate IHC score of 2+. More recently, a real-time polymerase chain reaction (PCR) assay using the LightCycler (R) has been developed for quantifying HER-2/neu gene amplification. In this study, we evaluated the sensitivity and specificity of a commercially available LightCycler assay as it compares to FISH. To determine whether this assay provides an accurate alternative for the determination of HER-2/neu status, we focused primarily on tumors that were deemed indeterminate or borderline status by IHC. Methods: Thirty-nine breast tumors receiving an IHC score of 2+ were evaluated by both FISH and LightCycler (R) technologies in order to determine whether quantitative real-time PCR provides an accurate alternative for the determination of HER-2/neu status. Results: We found a high concordance (92%) between FISH and real-time PCR results. We also observed that 10% of these tumors were positive for gene amplification by both FISH and real-time PCR. Conclusion: The data show that the results obtained for the gene amplification of HER-2/neu by real-time PCR on the LightCycler (R) instrument is comparable to results obtained by FISH. These results therefore suggest that real-time PCR analysis, using the LightCycler (R), is a viable alternative to FISH for reassessing breast tumors which receive an IHC score of 2+, and that a combined IHC and real-time PCR approach for the determination of HER-2 status in breast cancer patients may be an effective and efficient strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available